IN Brief:
- Product DEC85019 remains orderable, but NHS trusts are subject to maximum daily quantities.
- The disruption follows increased demand and longer lead times, with recovery currently expected by 31 October.
- Alternative products require local clinical review, while thresholds can change daily as stock and demand move.
NHS Supply Chain has placed a skin-disinfectant swabstick under daily ordering thresholds after increased demand and longer lead times disrupted normal supply.
The affected product is code DEC85019, a 1.6ml swabstick containing 2% chlorhexidine in 70% alcohol and supplied in packs of 50. PDI (EMEA) Limited informed NHS Supply Chain of the issue, which is currently expected to continue until 31 October 2026.
The product remains available through the NHS Supply Chain catalogue, but trusts are now allocated a maximum daily quantity under Protect Demand Management. Orders above a trust’s threshold can be reduced so that available stock is distributed across the health service.
Potential indirect alternatives are listed for customers, and NHS Supply Chain is seeking additional options. Trusts have been told to consult their own clinical experts before changing products because substitutions involving skin antisepsis require local assessment rather than a simple catalogue replacement.
Thresholds spread constrained stock
Protect Demand Management is designed for products that remain orderable but cannot meet unrestricted demand. NHS England’s allocation algorithm calculates a daily threshold for each trust, with quantities adjusted as the demand and supply position changes.
The available quantity is therefore not necessarily fixed for the duration of the disruption. A trust may see its threshold change from one day to the next, requiring procurement teams to monitor amended orders, current usage, and remaining local inventory more closely than under normal replenishment.
Where a trust exceeds its threshold through one or several requisition points, orders can be amended down to the daily limit. NHS Supply Chain says customers are informed of those amendments on the day before delivery, leaving a relatively short window to review stock, planned procedures, and possible alternatives.
The mechanism protects national continuity, but it transfers more planning work into local organisations. Hospitals need visibility of consumption across wards and departments, while central procurement teams need to prevent separate requisition points from ordering against the same constrained pool without coordination.
Skin-disinfectant swabsticks are small consumables, yet their supply illustrates why healthcare inventory is difficult to manage. Demand is distributed across many clinical settings, usage can move with procedure volumes, and a substitute may differ in formulation, presentation, application method, or approved use.
Nominal catalogue availability is therefore an incomplete measure. Stock may still be orderable nationally while individual trusts receive less than requested, and an alternative may be commercially available without being immediately suitable for every clinical pathway.
NHS Supply Chain has advised customers to review the product listing and the codes placed under Protect Demand Management. It is also monitoring the position with PDI and has warned that alternatives may experience temporary disruption because the wider market remains unsettled.
Substitution creates a second supply task
When a standard consumable becomes constrained, procurement teams need to manage both the original shortage and the introduction of alternatives. That can involve clinical review, product communication, stock segregation, revised ordering, and checks that the replacement is used in the correct setting.
Demand can also shift rapidly once buyers move towards the same substitute. A product that appears available at the start of a disruption may tighten as multiple trusts adopt it, particularly when suppliers share upstream manufacturing capacity or raw materials.
The 31 October resolution date should be treated as the current expectation rather than a guaranteed recovery point. Lead times can improve, but restored supply must also refill the pipeline, clear accumulated demand, and allow thresholds to be removed without triggering another order spike.
The issue sits within a wider effort to strengthen healthcare supply resilience. The UK-US pharmaceutical supply chain partnership targets concentrated manufacturing and shortage risks at policy level, while incidents such as DEC85019 show how disruption is experienced through individual product codes and daily hospital orders.
For trusts, the immediate control is disciplined consumption data. Usage by department, days of stock remaining, open orders, and approved substitutes need to be visible in one place if the organisation is to work within a changing daily threshold.
Supplier communication will be equally important. NHS Supply Chain has said it will update the notice as the stock position changes, and procurement teams will need to distinguish a revised allocation, a new alternative, and a confirmed return to normal supply.
The affected swabstick remains available, but availability is now conditional. Until normal lead times return, the operational objective is to prevent local over-ordering, preserve access across trusts, and ensure that any replacement product is introduced through clinical and procurement controls rather than hurried substitution.
